Palleos is pleased to announce the progress in the Phase 3 clinical trial for a novel treatment for moderate-to-severe chronic plaque-type psoriasis. Following the successful completion of the Clinical Trial Application submission, patient recruitment has officially started in Bulgaria.
The company has screened 14 patients, with the first participant now randomized and undergoing treatment. The remaining screened patients are currently in the screening process, and enrollment is proceeding as planned.
The study, for a novel treatment for moderate-to-severe chronic plaque-type psoriasis, will soon expand to Greece (September) and Poland (October), aiming for a total enrollment of over 200 patients across Eastern and Southern Europe.
Palleos is managing all aspects of this trial, ensuring a smooth and efficient process from clinical trial design to final documentation.
Interested in Palleos’ full-service CRO solutions? Reach out to info@palleos.com to discuss your clinical trial.
